{ "id": "epzsw5jjmg", "slug": "gemcitabine-and-irinotecan-regimen", "title": "Gemcitabine and irinotecan regimen", "updated": "2026-10-15", "topic_path": [ { "id": "life", "label": "Life and health", "api_url": "https://www.edgepedia.org/api/v1/topics/life" }, { "id": "life.health", "label": "Human health and medicine", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health" }, { "id": "life.health.medicines", "label": "Medicines and therapeutics", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.medicines" }, { "id": "life.health.medicines.cancer-chemotherapy", "label": "Cancer chemotherapy and regimens", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.medicines.cancer-chemotherapy" }, { "id": "life.health.medicines.cancer-chemotherapy.antimetabolite-and-fluoropyrimidine-regimens", "label": "Antimetabolite and fluoropyrimidine regimens", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.medicines.cancer-chemotherapy.antimetabolite-and-fluoropyrimidine-regimens" } ], "geo": [ { "id": "geo.nongeo.t1946.life.health.medicines.cancer-chemotherapy", "label": "Non-geographic · 1946 to 2000: Cancer chemotherapy and regimens", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.medicines.cancer-chemotherapy", "path": [ { "id": "geo.nongeo", "label": "Non-geographic", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo" }, { "id": "geo.nongeo.t1946", "label": "Non-geographic · 1946 to 2000", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946" }, { "id": "geo.nongeo.t1946.life", "label": "Life and health", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life" }, { "id": "geo.nongeo.t1946.life.health", "label": "Human health and medicine", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health" }, { "id": "geo.nongeo.t1946.life.health.medicines", "label": "Medicines and therapeutics", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.medicines" }, { "id": "geo.nongeo.t1946.life.health.medicines.cancer-chemotherapy", "label": "Cancer chemotherapy and regimens", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.medicines.cancer-chemotherapy" } ] } ], "excerpt": "The Gemcitabine and irinotecan regimen is a combination chemotherapy doublet studied in advanced pancreatic cancer; phase III results showed no significant survival benefit over gemcitabine monotherapy.", "snippet": "The Gemcitabine and irinotecan regimen is a combination chemotherapy doublet studied in advanced pancreatic cancer; phase III results showed no significant survival benefit over gemcitabine monotherapy.", "node": "life.health.medicines.cancer-chemotherapy.antimetabolite-and-fluoropyrimidine-regimens", "markdown": "# Gemcitabine and irinotecan regimen\n\nThe gemcitabine and [irinotecan regimen](https://www.edgepedia.org/irinotecan-regimen) is a combination chemotherapy doublet pairing the nucleoside analog gemcitabine with the topoisomerase I inhibitor irinotecan, studied mainly in advanced pancreatic cancer. Gemcitabine itself is FDA-approved as first-line treatment for locally advanced (nonresectable Stage II or III) or metastatic (Stage IV) pancreatic adenocarcinoma.[1](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06dd9d40-74fc-4409-93b1-a46be7126331) The doublet produced responses in phase II testing but did not improve survival over gemcitabine monotherapy in a randomized phase III trial,[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC2360678/) and the irinotecan-based regimen NALIRIFOX, which combines liposomal irinotecan, oxaliplatin, fluorouracil, and leucovorin but omits gemcitabine, was FDA-approved as a separate first-line option for metastatic pancreatic adenocarcinoma in 2024.[3](https://link.springer.com/article/10.1007/s40265-024-02133-1) • [17](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-irinotecan-liposome-first-line-treatment-metastatic-pancreatic-adenocarcinoma)\n\n| Key fact | Detail |\n|---|---|\n| Plain-doublet dosing (phase II) | Gemcitabine 1,000 mg/m² over 30 min followed by irinotecan 100 mg/m² over 90 min, IV, days 1 and 8 of 21-day cycles[4](https://ascopubs.org/doi/10.1200/JCO.2002.20.5.1182) |\n| Phase II efficacy (untreated advanced pancreatic cancer) | Response rate 20% (9/45), median time to progression 2.8 months, median survival 5.7 months, 1-year survival 27%[4](https://ascopubs.org/doi/10.1200/JCO.2002.20.5.1182) |\n| Phase III result | No significant survival benefit over gemcitabine monotherapy: median survival 6.4 vs 6.5 months[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC2360678/) |\n| NALIRIFOX dosing | Liposomal irinotecan 50 mg/m², oxaliplatin 60 mg/m², leucovorin 400 mg/m², fluorouracil 2,400 mg/m² over 46 h, days 1 and 15 of a 28-day cycle[5](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2823%2901366-1/fulltext) |\n| NAPOLI-3 outcome | Median OS 11.1 vs 9.2 months with gemcitabine/nab-paclitaxel (HR 0.84, p = 0.04); PFS 7.4 vs 5.6 months[6](https://ascopubs.org/doi/10.1200/JCO.2023.41.4_suppl.LBA661) |\n| Regulatory change | NALIRIFOX received US FDA approval in February 2024 for first-line metastatic pancreatic adenocarcinoma[7](https://www.nature.com/articles/s41467-026-68409-0) |\n| Characteristic toxicities | Diarrhea and myelosuppression; grade 3/4 neutropenia 27% with second-line nanoliposomal irinotecan plus 5-FU/folinic acid[8](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2815%2900986-1/abstract) |\n\n## How it works\n\nPreclinical studies by Bahadori and colleagues demonstrated synergistic cytotoxicity for the gemcitabine-irinotecan combination in a variety of cell lines, and this synergy observation forms the published rationale for combining the two drugs.[9](https://www.cancernetwork.com/view/irinotecan-management-patients-pancreatic-cancer)\n\n## How it is done\n\nThe phase II schedule that defined the plain doublet gave gemcitabine 1,000 mg/m² intravenously over 30 minutes followed immediately by irinotecan 100 mg/m² over 90 minutes, both on days 1 and 8 of repeated 21-day cycles.[4](https://ascopubs.org/doi/10.1200/JCO.2002.20.5.1182) A parallel phase I trial of 19 patients fixed gemcitabine at 1,000 mg/m² and escalated irinotecan from 50 through 75, 100, and 115 mg/m² on the same days-1-and-8 every-3-weeks schedule, recommending gemcitabine 1,000 mg/m² plus irinotecan 100 mg/m² for further testing.[9](https://www.cancernetwork.com/view/irinotecan-management-patients-pancreatic-cancer) A registry phase I in unresectable or metastatic solid tumors instead gave irinotecan over 90 minutes followed by gemcitabine over 30 minutes on days 1 and 15 of a 4-week cycle, testing the inverse drug sequence after the maximum tolerated dose was reached.[10](https://clinicaltrials.gov/study/NCT00004095)\n\nFor gemcitabine alone, the FDA label for pancreatic cancer specifies 1,000 mg/m² over 30 minutes weekly for 7 weeks, then a 1-week rest, then weekly on days 1, 8, and 15 of each 28-day cycle.[1](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06dd9d40-74fc-4409-93b1-a46be7126331) For liposomal-irinotecan regimens, patients should be premedicated with a corticosteroid such as dexamethasone plus an antiemetic at least 30 minutes before treatment.[3](https://link.springer.com/article/10.1007/s40265-024-02133-1)\n\n## Origin\n\nThe plain doublet's clinical development began with a phase I evaluation started in 1997 and a subsequent 19-patient phase I trial that established the recommended phase II dose,[9](https://www.cancernetwork.com/view/irinotecan-management-patients-pancreatic-cancer) followed by a multicenter phase II in previously untreated advanced pancreatic cancer.[4](https://ascopubs.org/doi/10.1200/JCO.2002.20.5.1182)\n\n## Variants\n\nSeveral named irinotecan-based regimens are distinct from the doublet rather than derived from it. **NALIRIFOX** combines liposomal irinotecan (ONIVYDE, historically nal-IRI, Ipsen Biopharmaceuticals) with oxaliplatin, fluorouracil, and leucovorin and contains no gemcitabine; the phase I/II study used 70 mg/m² free-base equivalent with 5-FU 2,400 mg/m² and leucovorin 400 mg/m²,[11](https://www.sciencedirect.com/science/article/pii/S0959804921001957) while the phase 3 NAPOLI 3 trial and approved labeling use 50 mg/m² liposomal irinotecan with oxaliplatin 60 mg/m², leucovorin 400 mg/m², and fluorouracil 2,400 mg/m² over 46 h on days 1 and 15 of a 28-day cycle.[5](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2823%2901366-1/fulltext) • [12](https://clinicaltrials.gov/ct2/show/NCT04083235) • [17](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-irinotecan-liposome-first-line-treatment-metastatic-pancreatic-adenocarcinoma) In second-line disease, **NAPOLI-1** tested nanoliposomal irinotecan 80 mg/m² plus fluorouracil and folinic acid after prior gemcitabine-based therapy.[8](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2815%2900986-1/abstract) **PAN-HEROIC-1** used the Chinese liposomal formulation HR070803 (60 mg/m² over 90 min, equivalent to 56.5 mg/m² irinotecan [free base](https://www.edgepedia.org/free-base)) with 5-FU 2,000 mg/m² and leucovorin 200 mg/m² every two weeks.[13](https://www.nature.com/articles/s41392-024-01948-4) A three-drug phase II added 5-fluorouracil to the plain doublet (irinotecan 75 mg/m², gemcitabine 1,000 mg/m², and 5-FU 2,000 mg/m² over 24 h on days 1 and 8 of 21-day cycles).[14](https://karger.com/ocl/article/72/5-6/279/238403/Irinotecan-plus-Gemcitabine-and-5-Fluorouracil-in)\n\n## Applications\n\nIn the phase II trial of 45 previously untreated patients with unresectable or metastatic pancreatic cancer, the confirmed response rate was 20% (95% CI 8%–32%), median time to progression 2.8 months, median survival 5.7 months, and 1-year survival 27%; CA 19-9 fell by 50% or more in 13 of 44 patients (30%), correlating with radiographic tumor-area change (r = .67, P < .001).[4](https://ascopubs.org/doi/10.1200/JCO.2002.20.5.1182) The subsequent phase III randomized 145 patients to gemcitabine monotherapy or the doublet (gemcitabine days 1 and 8 plus irinotecan 300 mg/m² on day 8 every 3 weeks) and found no significant survival difference: median survival 6.4 vs 6.5 months, 1-year survival 24.3% vs 21.8%, median time to progression 2.8 vs 2.9 months, and overall response rate 15% vs 10% (P = 0.387).[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC2360678/)\n\nThe liposomal regimens, however, rest on their own evidence and occupy separate clinical roles.[17](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-irinotecan-liposome-first-line-treatment-metastatic-pancreatic-adenocarcinoma) In NAPOLI-3, NALIRIFOX improved median overall survival to 11.1 months versus 9.2 months with gemcitabine plus nab-paclitaxel (HR 0.84, 95% CI 0.71–0.99; p = 0.04) and progression-free survival to 7.4 versus 5.6 months (HR 0.70, p = 0.0001).[6](https://ascopubs.org/doi/10.1200/JCO.2023.41.4_suppl.LBA661) NALIRIFOX received US FDA approval in February 2024 for first-line metastatic pancreatic adenocarcinoma, entered the 2024 CSCO guidelines as a Category 1A Level II regimen, and was designated a preferred Category 1 option for metastatic disease in the NCCN 2025 guidelines.[7](https://www.nature.com/articles/s41467-026-68409-0) A meta-analysis of 7 phase 3 trials (2,581 patients) found NALIRIFOX and [FOLFIRINOX](https://www.edgepedia.org/folfirinox) associated with similar progression-free survival (7.4 vs 7.3 months) and overall survival (11.1 vs 11.7 months; HR 1.06, 95% CI 0.81–1.39; P = .65), both longer than gemcitabine/nab-paclitaxel (PFS 5.7 months; HR vs NALIRIFOX 1.45, P < .001).[15](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2813517) In second-line disease after gemcitabine-based therapy, NAPOLI-1 extended median overall survival to 6.1 months versus 4.2 months with fluorouracil/folinic acid alone (HR 0.67, p = 0.012), while 120 mg/m² monotherapy did not differ (4.9 vs 4.2 months).[8](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2815%2900986-1/abstract) PAN-HEROIC-1 similarly improved median overall survival to 7.4 versus 5.0 months with placebo plus 5-FU/LV (HR 0.63, p = 0.0019) in 298 previously gemcitabine-treated patients.[13](https://www.nature.com/articles/s41392-024-01948-4)\n\n## Limitations and alternatives\n\nThe plain doublet's central limitation is its phase III failure to improve survival over gemcitabine monotherapy,[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC2360678/) which leaves it without a demonstrated first-line role compared with FOLFIRINOX or gemcitabine/nab-paclitaxel. Dose-limiting diarrhea appeared in the phase I work, occurring in two of seven patients at the 115 mg/m² irinotecan dose.[9](https://www.cancernetwork.com/view/irinotecan-management-patients-pancreatic-cancer) Across irinotecan-based regimens, diarrhea and myelosuppression dominate the toxicity profile: in NAPOLI-1, grade 3/4 events in the combination arm included neutropenia in 27% (32/117), diarrhea in 13%, vomiting in 11%, and fatigue in 14%.[8](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2815%2900986-1/abstract)\n\n**UGT1A1 genotyping** UGT1A1 genotyping affects irinotecan dosing in separate liposomal-irinotecan regimens.[17](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-irinotecan-liposome-first-line-treatment-metastatic-pancreatic-adenocarcinoma) UGT1A1 is the crucial enzyme in irinotecan metabolism, and gene mutations with decreased enzyme activity increase the incidence of diarrhea and neutropenia.[13](https://www.nature.com/articles/s41392-024-01948-4) In PAN-HEROIC-1, all patients underwent UGT1A1 genotyping before treatment, and patients homozygous for UGT1A1*28 or *6 began at a reduced HR070803 dose of 50 mg/m² in the first cycle, escalating to standard dose if no drug-related toxicity occurred.[13](https://www.nature.com/articles/s41392-024-01948-4) The GENERATE trial required wild-type or single heterozygous UGT1A1 genotypes for eligibility.[16](https://pmc.ncbi.nlm.nih.gov/articles/PMC12573688/)\n\nCompared with its alternatives, NALIRIFOX showed lower grade 3+ hematologic toxicity than FOLFIRINOX (grade 3+ platelet decrease 1.6% vs 11.8%) but more severe diarrhea than gemcitabine/nab-paclitaxel (20.3% vs 15.7%).[15](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2813517) The NCCN notes that NALIRIFOX does not appear to have an advantage over FOLFIRINOX and adds more expense, and the NAPOLI 3 median overall survival improvement did not meet WHO, ASCO, or ESMO thresholds for clinically meaningful benefit; ESMO and ASCO guidelines had not yet included NALIRIFOX at the time of that review.[3](https://link.springer.com/article/10.1007/s40265-024-02133-1) In Japan, the GENERATE trial of mFOLFIRINOX or S-IROX versus nab-paclitaxel plus gemcitabine was terminated for futility after median overall survival favored the gemcitabine/nab-paclitaxel arm (14.0 and 13.6 vs 17.1 months).[16](https://pmc.ncbi.nlm.nih.gov/articles/PMC12573688/)\n\n## References\n\n1. [DailyMed label: Gemcitabine hydrochloride injection, solution](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06dd9d40-74fc-4409-93b1-a46be7126331)\n2. [A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer](https://pmc.ncbi.nlm.nih.gov/articles/PMC2360678/)\n3. [Liposomal Irinotecan: A Review as First-Line Therapy in Metastatic Pancreatic Adenocarcinoma | Drugs](https://link.springer.com/article/10.1007/s40265-024-02133-1)\n4. [Irinotecan Plus Gemcitabine Induces Both Radiographic and CA 19-9 Tumor Marker Responses in Patients With Previously Untreated Advanced Pancreatic Cancer](https://ascopubs.org/doi/10.1200/JCO.2002.20.5.1182)\n5. [NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2823%2901366-1/fulltext)\n6. [NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)](https://ascopubs.org/doi/10.1200/JCO.2023.41.4_suppl.LBA661)\n7. [NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial | Nature Communications](https://www.nature.com/articles/s41467-026-68409-0)\n8. [Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2815%2900986-1/abstract)\n9. [Irinotecan in the Management of Patients with Pancreatic Cancer](https://www.cancernetwork.com/view/irinotecan-management-patients-pancreatic-cancer)\n10. [Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors (NCT00004095)](https://clinicaltrials.gov/study/NCT00004095)\n11. [First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study](https://www.sciencedirect.com/science/article/pii/S0959804921001957)\n12. [A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment](https://clinicaltrials.gov/ct2/show/NCT04083235)\n13. [Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial](https://www.nature.com/articles/s41392-024-01948-4)\n14. [Irinotecan plus Gemcitabine and 5-Fluorouracil in Advanced Pancreatic Cancer: A Phase II Study (Oncology, Karger)](https://karger.com/ocl/article/72/5-6/279/238403/Irinotecan-plus-Gemcitabine-and-5-Fluorouracil-in)\n15. [NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2813517)\n16. [Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II/III Trial](https://pmc.ncbi.nlm.nih.gov/articles/PMC12573688/)\n17. [Fda Approves Irinotecan Liposome First Line Treatment Metastatic Pancreatic Adenocarcinoma, fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-irinotecan-liposome-first-line-treatment-metastatic-pancreatic-adenocarcinoma)\n\n---\n*Topic: Encyclopedia › Life and health › Human health and medicine › Medicines and therapeutics › Cancer chemotherapy and regimens › Antimetabolite and fluoropyrimidine regimens*\n\n*Initially written Sep 29, 2026 · Edited: Oct 15, 2026*\n\n*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*\n\nLicense: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license\n", "same_as": [], "url": "https://www.edgepedia.org/gemcitabine-and-irinotecan-regimen", "markdown_url": "https://www.edgepedia.org/gemcitabine-and-irinotecan-regimen.md", "license": { "name": "Edgepedia Community License 1.0", "url": "https://www.edgepedia.org/edgepedia/license", "summary": "Free with credit, commercial use included. AI training is open to everyone. For other uses, organizations over USD 100M in revenue or 100M monthly users license separately.", "spdx": "LicenseRef-Edgepedia-Community-1.0" }, "credit": "\"Gemcitabine and irinotecan regimen\", Edgepedia (EdgeChat), https://www.edgepedia.org/gemcitabine-and-irinotecan-regimen. Edgepedia Community License 1.0.", "credit_md": "\"[Gemcitabine and irinotecan regimen](https://www.edgepedia.org/gemcitabine-and-irinotecan-regimen)\", Edgepedia (EdgeChat), [https://www.edgepedia.org/gemcitabine-and-irinotecan-regimen](https://www.edgepedia.org/gemcitabine-and-irinotecan-regimen). [Edgepedia Community License 1.0](https://www.edgepedia.org/edgepedia/license).", "credit_html": "\"Gemcitabine and irinotecan regimen\", Edgepedia (EdgeChat), https://www.edgepedia.org/gemcitabine-and-irinotecan-regimen. Edgepedia Community License 1.0.", "speakable": "The Gemcitabine and irinotecan regimen is a combination chemotherapy doublet studied in advanced pancreatic cancer; phase III results showed no significant survival benefit over gemcitabine monotherapy." }